University of Houston establishes new health care business innovation chair thanks to $2M gift

donation station

Elaine Finger's donation will go toward an endowed chair to advance education, research and innovation in business and health care at the University of Houston. Photo via uh.edu

A Houston philanthropist made a $2 million gift to the University of Houston to advance health care business innovation

Elaine Finger's donation will go toward an endowed chair to advance education, research and innovation in business and health care at the University of Houston. The Elaine W. Finger Endowed Chair in Health Care Business Innovation is a joint appointment in the C.T. Bauer College of Business and the Tilman J. Fertitta Family College of Medicine. The project will aim to catalyze innovative advancements to help the university into a leading hub for innovative solutions.

The endowment was made through the Bauer Foundation, and will be matched dollar-for-dollar via UH’s Aspire Fund. The Aspire Fund is a grant program created by the gift of an anonymous donor that matches all eligible gifts up to $50 million — for a total of $100 million — and is aimed to assist in education, health care innovation research, and industry outreach.

“An investment in health care business innovation is far more than a gift, it is a visionary commitment to the future of healthcare in Houston and beyond,” Diane Z. Chase, UH senior vice president for academic affairs and provost, says in a news release. “The establishment of this Chair is a testament to our shared dedication to developing solutions that will shape the health care landscape for generations to come.”

Bauer College launched the Healthcare Business Institute, or HBI, this summer to address research and innovative solutions for quality, cost and access concerns. HBI also works to connect students, faculty and researchers from Bauer, the Fertitta Family College of Medicine and the highly ranked health law program at the UH Law Center, and other UH programs.

UH will search for a new chair that according to the university, “will be considered a thought leader in health care innovation" and who is of high national prominence and able to elevate the stature of the University of Houston by bringing a record of achievements recognized by membership in the National Academy of Science, National Academy of Medicine or another national academy related to the field of study.

Ravi Aron, research director and professor of health care strategy, currently leads HBI.

UH's C. T. Bauer College of Business will house the newly launched Healthcare Business Institute. Photo via Getty Images

University of Houston introduces institute to bring business solutions to health care industry

medical biz

The University of Houston announced this month that it has now launched its new Healthcare Business Institute, which will work with medical and business leaders as well as students to find solutions to pressing issues in the health care industry, such as high costs, access to care and new innovative technologies.

The institute will be part of the university's C. T. Bauer College of Business and led by Ravi Aron, research director and professor of health care strategy and technology in the Bauer College Department of Decision & Information Sciences, and Dr. Edward Kroger, the administrative director of the center.

“Providers are facing increasingly limited reimbursement from the U.S. government, insurers and employers. The industry is, therefore, struggling with finding new ways to increase value by improving quality and decreasing cost,” Aron says in a statement. “This is complicated by the fact that the industry is the most heavily regulated in the country. While policy, regulations and the government all have roles to play, efficient care delivery also requires businesses–small, medium, large and startups-to play a significant role in delivering effective and efficient care.”

The institute plans to bring together stakeholders from device makers and pharmaceutical companies to angel investors and educators to address many of these issues. Faculty and partners will release impactful research on topics such as hospital operations, new health care technologies, AI and machine learning in hospital contexts, emerging financial models in health care and a number of other topics.

Research will be shared in a new practitioner-facing Knowledge Portal that will feature a journal, editorials, and other media components like blogs, videos and audio.

The HBI will also have an educational component, with formal degree-based and shorter non-degree tracts, as well as a masters program related to health care leadership. Multiple executive education programs are also in the works.

“This unique combination of researchers, educationists and students will also benefit by connecting to perhaps the world’s most diversified health care ecosystem,” Aron says in the statement.

And Houston is the right place to house such an institute, says Bauer College Dean and Cullen Distinguished Chair Professor Paul A. Pavlou.

“Technology, data, and AI are enabling unprecedented advances in medicine, and Houston’s impressive health care network presents an exciting opportunity for a Healthcare Business Institute,” Pavlou says in the release. “Not only is Houston home to the Texas Medical Center, UH is the only university in Houston that includes a large number of health care researchers at the Bauer College of Business, a world-ranked health law program at the UH Law Center, a computer science department with many distinguished research faculty, and a new College of Medicine."

“The opportunity for meaningful collaboration among health care researchers, industry leaders, and students through HBI will be a tremendous asset for Houston with the potential for local, national and global impact,” he continues.

Earlier this summer, UH announced plans to open a 70,000-square-foot innovation hub next to the M.D. Anderson Library on UH's main campus in 2025. It's slated to house a makerspace, the Cyvia and Melvyn Wolff Center for Entrepreneurship, the Energy Transition Institute, innovation programs, and Presidential Frontier Faculty labs and offices.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston startup debuts bio-based 'leather' fashion collection in Milan

sustainable fashion

Earlier this month, Houston-based Rheom Materials and India’s conscious design studio Econock unveiled a collaborative capsule collection that signaled more than just a product launch.

Hosted at Lineapelle—long considered the global epicenter of the world's premier leather supply chain—in the vaulted exhibition halls of Rho-Fiera Milano, the collection centered around Rheom’s 91 percent bio-based leather alternative, Shorai.

It was a bold move, one that shifted sustainability from a concept discussed in panel sessions to garments that buyers could touch and wear.

The collection featured a bomber-style jacket, an asymmetrical skirt and a suite of accessories—all fabricated from Shorai.

The standout piece, a sculptural jacket featuring a funnel neck and dual-zip closure, was designed for movement, challenging assumptions about performance limitations in bio-based materials. The design of the asymmetrical skirt was drawn from Indian armored warrior traditions, according to Rheom, with biodegradable corozo fasteners.

Built as a modular wardrobe rather than isolated pieces, the collection reflects a shared belief between Rheom and Econock in designing objects that adapt to daily life, according to the companies.

The collection was born out of a new partnership between Rheom and Econock, focused on bringing biobased materials to the market. According to Rheom, the partnership solves a problem that has stalled the adoption of many next-gen textiles: supply chain friction.

While Rheom focuses on engineering scalable bio-based materials, New Delhi-based Econock brings the complementary design and manufacturing ecosystem that integrates artisans, circular materials and production expertise to translate the innovative material into finished goods.

"This partnership removes one of the biggest barriers brands face when adopting next-generation materials,” Megan Beck, Rheom’s director of product, shared in a news release. “By reducing friction across the supply chain, Rheom can connect brands directly with manufacturers who already know how to work with Shorai, making the transition to more sustainable materials far more accessible.”

Sanyam Kapur, advisor of growth and impact at Econock, added: “Our partnership with Rheom Materials represents the benchmark of responsible design where next-gen materials meet craft, creativity, and real-world scalability.”

Rheom, formerly known as Bucha Bio, has developed Shorai, a sustainable leather alternative that can be used for apparel, accessories, car interiors and more; and Benree, an alternative to plastic without the carbon footprint. In 2025, Rheom was a finalist for Startup of the Year in the Houston Innovation Awards.

Shorai is already used by fashion lines like Wuxly and LuckyNelly, according to Rheom. The company scaled production of the sugar-based material last year and says it is now produced in rolls that brands can take to market with the right manufacturer.

Houston startup debuts leather alternative fashion collection in Milan

Houston clean energy co. secures $100M to deploy tech on global scale

Going Global

Houston-based Utility Global has raised $100 million in an ongoing Series D round to globally deploy its decarbonization technology at an industrial scale.

The round was led by Ara Partners and APG Asset, according to a news release. Utility plans to use the funding to expand manufacturing, grow its teams and support its commercial developments and partnerships.

“This financing marks a critical step in Utility’s transition from a proven technology to full-scale global commercial execution,” Parker Meeks, CEO and president of Utility Global, said in the release. “Industrial customers are no longer looking for pilots or promises; they need deployable solutions that work within existing assets and deliver true economic industrial decarbonization today that is operationally reliable and highly scalable. Utility’s technology produces both economic clean hydrogen and capture-ready CO2 streams, and this capital enables us to scale and deploy that impact globally with speed, discipline, and rigor.”

Utility Global's H2Gen technology produces low-cost, clean hydrogen from water and industrial off-gases without requiring electricity. It's designed to integrate into existing industrial infrastructure in hard-to-abate assets in the steel, refining, petrochemical, chemical, low-carbon fuels, and upstream oil and gas sectors.

“Utility is tackling one of the most difficult challenges in the energy transition: decarbonizing hard‑to‑abate industrial sectors,” Cory Steffek, partner at Ara Partners and Utility Global board chair, said in the release. “What sets Utility apart is its ability to compete head‑to‑head with conventional fossil‑based solutions on cost and reliability, even as it materially reduces emissions. With this new funding, Utility is well-positioned for its next chapter of commercial growth while maintaining the technical excellence and capital discipline that have defined its development to date.”

Utility Global reached several major milestones in 2025. After closing a $53 million Series C, the company agreed to develop at least one decarbonization facility at an ArcelorMittal steel plant in Brazil. It also signed a strategic partnership with California-based Kyocera International Inc. to scale global manufacturing of its H2Gen electrochemical cells.

The company also partnered with Maas Energy Works, another California company, to develop a commercial project integrating Maas’ dairy biogas systems with H2Gen to produce economical, clean hydrogen.

"These projects were never intended to stand alone. They anchor a deep and growing pipeline of commercial projects now in development globally across steel, refining, chemicals, biogas and other hard-to-abate sectors worldwide, Meeks shared in a 2025 year-in-review note. He added that 2026 would be a year of "focused acceleration to scale."

---

This article originally appeared on EnergyCapitalHTX.com.

Houston Methodist awarded $4M grant to recruit head of Neal Cancer Center

new hire

Armed with a $4 million state grant, the Houston Methodist Academic Institute has recruited a renowned expert in ovarian and endometrial cancer research to lead the Dr. Mary and Ron Neal Cancer Center.

The grant, provided by the Cancer Prevention and Research Institute of Texas, enabled the institute to lure Dr. Daniela Matei away from Northwestern University’s Feinberg School of Medicine in Chicago. There, she is the Diana Princess of Wales Professor in Cancer Research and chief of the Division of Reproductive Science in Medicine.

Matei will succeed Dr. Jenny Chang, who was hired last year to run the Houston Methodist Academic Institute.

At the Neal Cancer Center, located in the Texas Medical Center complex, oncologists work on innovations in cancer research, treatment, and technology. The center opened in 2021 after the Neals donated $25 million to expand Houston Methodist’s cancer research capabilities. It handles about 7,000 new cases each year involving more than two dozen types of cancer.

U.S. News & World Report puts Houston Methodist Hospital at No. 19 among the country’s best hospitals for cancer care, two spots below Chicago’s Northwestern Memorial Hospital. The University of Texas MD Anderson Cancer Center in Houston sits at No. 1 on the list.

Matei’s research related to ovarian and endometrial cancer holds the potential to benefit tens of thousands of American women. The American Cancer Society estimates:

  • 21,010 women in the U.S. will be diagnosed with ovarian cancer, and 12,450 women will die from it.
  • 68,270 women in the U.S. will be diagnosed with endometrial cancer, and 14,450 women will die from it.

Matei is leaving Northwestern in the wake of widespread cuts in federal funding for medical research. The National Institutes of Health (NIH) has canceled or frozen tens of millions of dollars in grants for Northwestern, the Wall Street Journal reports, and the university has been plugging the gaps with its own money.

“The university is totally keeping us on life support,” Matei told the newspaper last year. “The big question is for how long they can do this.”

According to the Wall Street Journal, Matei’s $5 million NIH grant supporting 69 cancer trials has been caught up in the federal funding chaos, so Northwestern stepped in to cover trial expenses such as nurses’ salaries and diagnostic procedures.

Trial participants include some patients with rare, incurable tumors who are undergoing experimental treatments aligned with the genetics of their condition, the newspaper says.

“It’s certainly a life-and-death situation for cancer patients on these trials,” Matei said in 2025.

Matei is among the beneficiaries of more than $15 million in grants approved February 18 by CPRIT’s board. The grants went toward recruiting five cancer researchers to institutions in Texas.

One of those grants, totaling $1.5 million, went to the University of Houston to recruit Akash Gupta, a research scientist at MIT’s Koch Institute for Integrative Cancer Research. The remaining grants went to recruit scientists to The University of Texas at Dallas and The University of Texas Southwestern Medical Center.
View All Listings